NU 6027 – 50 mg

Brand:
Cayman
CAS:
220036-08-8
Storage:
-20
UN-No:
Non-Hazardous - /

Cyclin-dependent kinases (CDKs) play a key role in regulating cell division by phosphorylating distinct substrates in different phases of the cell cycle. Cell cycle deregulation in many cancers often results from altered CDK activity. Thus, CDKs are potential pharmacological targets for anticancer agents. NU 6027 inhibits both CDK1 and CDK2 with IC50 values of 2.9 and 2.2 µM, respectively.{21732} It has been shown to inhibit cellular ataxia telangiectasia mutated and Rad3-related kinase activity (IC50 = 6.7 µM) and impair G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin.{26368}  

 

SKU: - Category:

Description

An inhibitor of both CDK1 and CDK2 (IC50s =2.9 and 2.2 µM, respectively); inhibits cellular ataxia telangiectasia mutated and Rad3-related kinase activity (IC50 = 6.7 µM) and impairs G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin


Formal name: 6-(cyclohexylmethoxy)-5-nitroso-2,4-pyrimidinediamine

Synonyms: 

Molecular weight: 251.3

CAS: 220036-08-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|ATM||Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Death||Research Area|Cancer|Cell Signaling|ATM Signaling